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Nine-year experience of bovine pericardium patch
angioplasty during carotid endarterectomy
Giorgio M. Biasi, MD, Sarah Sternjakob, MD, Paolo M. Mingazzini, MD, and Stefano A. Ferrari, MD,
Milan, Italy
Purpose: This paper examines the clinical results of a 9-year experience in which the incidence of major (stroke and death)
perioperative events and of recurrent stenosis (>60%) after carotid endarterectomy performed with a direct suture (DS)
of the arteriotomy versus bovine pericardium patch angioplasty (BPPA) are compared.
Methods and Materials: A total of 517 carotid endarterectomies were included in this nonrandomized study and were
divided into two groups: group DS with 194 procedures and group BPPA with 323 procedures. All patients were entered
in a follow-up program that ranged from 1 to 108 months (mean, 56.4 months) and included color duplex scan
examinations at 1, 3, 6, and 12 months after surgery and every year thereafter.
Results: The number of major (stroke and death) perioperative cerebrovascular accidents was eight (4.1%) in the DS
Group and five (1.5%) in the BPPA group (P  .066). One death occurred in the DS group, and three occurred in the
BPPA Group (P .517). The four deaths in both groups were the result of strokes. No statistically significant difference
was found in terms of early neurologic complications between the two groups. During the first year of follow-up study,
the rate of restenosis >60% and occlusion was significantly lower in the BPPA group. Thereafter, the difference was not
significant.
Conclusion: In our experience, the use of BPPA or DS during carotid endarterectomy procedure does not cause a
significantly different rate of perioperative major events (stroke or death) in the two groups. The incidence rate of
restenosis is lower in the first year after surgery with BPPA, but in subsequent years, no significant difference in restenosis
is seen. The early and late postoperative results with BPPA compare favorably with the reported data from literature with
the use of other patch materials. (J Vasc Surg 2002;36:271-7.)
Carotid endarterectomy (CEA) has become one of the
most commonly performed vascular operations and has
long been recognized as the best procedure to reduce the
incidence of cerebral ischemia in symptomatic and asymp-
tomatic significant internal carotid stenosis.1-3 The goals of
carotid surgery are to relieve neurologic symptoms and
prevent stroke and, by doing so, improve the quality of life
and hopefully lengthen survival.
Long debated, and still debated among vascular sur-
geons, is the question of the best technique in terms of early
and late complications. Several methods have been pro-
posed, among which direct suture (DS) of the arterioto-
my,4 eversion CEA,5,6 and patch angioplasty7-9 are the
most widely performed. The indication for patch angio-
plasty—easier closure of the arteriotomy, lower incidence
rate of perioperative thrombosis, and late recurrent steno-
ses—has long been advocated.10,11
The selection of patch material is even more controver-
sial, and several autogenous (saphenous or internal/exter-
nal jugular vein) or synthetic materials (polytetrafluoroeth-
ylene or Dacron) are diffusely used. The autologous vein
seems to be favored by most authors, and satisfactory early
and late results are currently reported. But, although the
formation of aneurysmal dilatations and vein disruptions
after saphenous vein patch endarterectomy seems to be
rather uncommon, such reports still are found in the liter-
ature.12,13 The use of a polytetrafluoroethylene patch is
often complicated with disturbing bleeding from the suture
holes and necessitates a longer operating time; polytetra-
fluoroethylene has been reported to be a noncompliant
patch and to present minimal and inconsistent endotheliza-
tion.14 Higher potential for infection, dilatation at high-
pressure sites, and thrombogenic flow surface are the re-
ported disadvantages of the Dacron patch.
The ideal material for patch angioplasty should be
similar in consistency to the native artery and easy to
handle, like autogenous tissue, with excellent host tissue
response, should support a balanced endothelialization and
resist suture line bleeding, and, finally, should be indicated
also for the reconstruction of different arterial vessels and
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arteriovenous access revisions. A particular patch material,
the bovine pericardium, which seems to have these charac-
teristics, has been described and used in different surgical
procedures: in cardiac surgery for acquired diseases or
congenital heart defects,15-17 in thoracic surgery to reduce
air leak,18and in neurosurgery for dural grafts.19
Only a few reports can be found in the literature
concerning the use of bovine pericardium patch during
CEA procedures.20,21 Our initial experience with a glutar-
aldehyde-treated bovine pericardial patch was reported in
1996,22 and in this retrospective, nonrandomized study,
our postoperative results during a 9-year follow-up period
are reported.
METHODS AND MATERIALS
From September 1991 to August 2000 at the Division
of Vascular Surgery of the University of Milano-Bicocca,
Bassini/San Gerardo Teaching Hospitals, two groups of
patients, for a total of 517 consecutive CEAs, were retro-
spectively analyzed. The utility of a patch has been sug-
gested with carotid lesion characteristics, conforming crite-
ria for obligatory patching that were defined by Clagett,
Patterson, and Ficher.10 Damaged and unsuitable arterial
margins and the absence of a natural reentry in the lumen at
the distal end of the arteriotomy also are considered criteria
for patching.11 Our indications for patching were reported
in a previous paper.22
In 194 cases (37.5%), a DS (DS Group) was performed
for closure of the carotid arteriotomy, and in 323 cases
(62.5%), a patch angioplasty with bovine pericardium patch
angioplasty (BPPA group) was used. The mean age of the
patients who underwent the 517 CEA procedures in
groups DS and BPPA was 69  8.9 years (range, 48 to 89
years). The 301 symptomatic cases (58.2%) were registered
as complete strokes, amaurosis fugax, transient hemispheric
symptoms, and nonhemispheric symptoms. The symptom-
free cases numbered 216 (41.8%; Table I). A total of 323
CEAs were performed in male patients, and a total of 125
were performed in female patients.
Real-time B-mode imaging, with color duplex scanner
(Acuson 128/Sequoia 512, Acuson Corp, Mountain View,
Calif), with a 7.5-MHz probe to identify the grade of
stenosis and the characteristics of the plaques, was per-
formed in all cases. The peak flow velocity measurement
was used to determine the level of maximal stenosis. Digital
subtraction angiography was done in 84.5% of the cases,
with equal distribution in the two groups. The percentage
of stenosis was calculated after European Carotid Surgery
Trial criteria.2 Most patients had stenosis of the internal
carotid artery 70%. In 26 cases in group DS and in 50
cases in group BPPA (total, 14.7%), the percentage of
stenosis was 70%, but in these cases, the lesions were
represented by ulcerated plaques or by soft low echogenic
plaques with or without a necrotic or hemorrhagic core,
which in our experience resulted in high risk for brain
embolization.21,23 These patients underwent operation
even though their conditions were asymptomatic.
The main preoperative risk factors (dislipidemia, hyper-
tension, diabetes mellitus, coronary artery disease, periph-
eral arterial occlusive disease, cigarette smoking) also were
evaluated. No statistically significant difference was re-
corded in the two groups (Table I).
All patients underwent preoperative electroencephalo-
gram and cerebral computed tomographic scanning and
underwent operation with general anesthesia, with con-
tinuing electroencephalogram monitoring and systemic he-
parinization (2500 units intravenously) at the time of ca-
rotid cross clamping. As reported in one of our previous
publications, the administration of a low dose of heparin
intravenously during CEA resulted in a reduction in hem-
orrhagic complications without any increase in thrombotic
events.22 Arteriotomy was carried out on the common
carotid artery (mean length, 3.5 cm) and prolonged on the
internal carotid artery (mean length, 2.6 cm). A Pruitt-
Table I. Preoperative neurologic symptoms in 517 CEAs and distribution within each study group of general risk
factors for atherosclerosis
DS BPPA P value (2 test)
Clinical manifestations
Symptomatic patients 117 (60.3%) 184 (57.0%) .45
Complete strokes 19 (9.8%) 27 (8.3%) .58
Transient hemispheric symptoms 76 (39.2%) 125 (38.7%) .91
Non-transient hemispheric symptoms 10 (5.1%) 13 (4.0%) .55
Amaurosis fugax 12 (6.2%) 19 (5.9%) .89
Symptom-free 65 (33.5%) 151 (46.7%) .003
General risk factors
Smoker 40 (22.9%) 56 (20.4%) .52
Exsmoker 112 (64.4%) 163 (59.5%) .30
PAOD 58 (33.3%) 71 (25.9%) .09
Diabetes mellitus 42 (24.1%) 71 (25.9%) .67
Coronary artery disease 56 (32.2%) 84 (30.6%) .73
Hypertension 126 (72.4%) 197 (71.9%) .90
Dyslipidemia 58 (33.3%) 82 (29.9%) .45
PAOD, Peripheral arterial occlusive disease.
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Inhara shunt (Ideas for Medicine, Cryolife Co, St Peters-
burg, Fla) was inserted selectively on the basis of the
appearance of electroencephalogram tracing abnormalities
after carotid clamping. In all patients in group BPPA, a
processed bovine pericardium patch (Vascu-Guard, Bio-
Vascular Inc, Saint Paul, Minn) was used. This patch was
stabilized with glutaraldehyde and then stored and shipped
in sterile water and 1% propylene oxide. Only a 3-minute
rinsing in sterile physical saline solution was necessary to
remove the residual propylene oxide before implant of the
patch. A prolene 6/0 continuous suture was applied in all
cases in both groups. The surgical technique adopted was
described in more detail in a previous publication.22 The
intraoperative assessment of the hemodynamic results after
CEA was obtained with continuous wave Doppler spectral
analysis.
All patients underwent antiplatelet therapy (acetylsali-
cylic acid 160 mg/day or ticlopidine hydrochloride 250
mg/day in case of gastric intolerance) within 24 hours after
surgery. Control carotid duplex scans were performed at 1,
3, 6, and 12 months after surgery and yearly thereafter to
check the incidence of carotid restenosis. For the restenosis
classification, we used the criteria suggested by Bernstein,
Torem, and Dillet.24 The reduction of the vessel diameter
by 0% to 19% was considered as nonsignificant restenosis,
by 20% to 49% as intermediate restenosis, and by more than
50% as significant restenosis. Recurrent disease is defined by
most authors as 60% restenosis. Restenoses 80% were
included in a closer follow-up control program and consid-
ered for redo surgery.
The Fisher exact test was used to compare the short-
term complication rate, and the 2 test was used to com-
pare clinical manifestation, risk factors, operative proce-
dures, and overall late restenosis rate. For the long-term
data, we used the Kaplan-Meier method curve to compare
the incidence rates of occlusion or restenosis 60% during
follow-up study of two groups of patients (112 DS versus
178 BPPA; 290 patients).
RESULTS
CEA procedures were performed on 323 men and 125
women. One hundred and seventy-eight male patients
needed angioplasty with bovine pericardium patch, and
198 needed DS. Sixteen DS angioplasties and 125 BPPAs
were performed in the female group, with a statistically
significant difference between the two groups (male: 47.3%
for DS versus 52.5% for BPPA; P  .001; female: 16% for
DS versus 88.7% for BPPA; P  .001).
The mean carotid occlusion time, on the total CEAs in
the two groups, was 40  16.1 minutes and in particular
was 30.0  12.5 minutes in group DS and 47.7  15.1
minutes in group BPPA. On the basis of the appearance of
electroencephalogram abnormalities after carotid clamp-
ing, a Pruitt-Inhara shunt was inserted in 42 patients in
group DS and in 94 in group BPPA. Intimal tacking sutures
were applied in 57 procedures, 27 and 30, respectively, in
the DS and BPPA groups. Revision of the endarterectomy
after intraoperative ultrasound scan assessment of an inad-
equate carotid flow was necessitated in four cases (Table
II).
Thirteen major (stroke and death) early postoperative
complications (2.5%) occurred, with 13 strokes (2.5%),
four of which were followed by death (0.8%). In our
observation, a trend was seen toward more postoperative
complications associated with the DS group than with the
BPPA group, although this trend just failed to reach statis-
tical significance (stroke: 4.1% for DS versus 1.5% for
BPPA; P .066; death: 0.5% for DS versus 0.9% for BPPA;
P  .517; Table III). Twenty-two transient ischemic at-
tacks (4.2%) were recorded, seven (3.6%) in the DS group
and 15 (4.6%) in the BPPA group. Transient nerve palsy
occurred in 21 cases (3.5%): eight facial, one glossopharin-
geal, 10 hypoglossus, and two laryngeal, without a statisti-
cally significative difference between the two groups. No
infection, rupture, or dilation was recorded in the two
groups.
From 1 to 108 months, 290 patients were followed
with duplex scan assessment at 1, 3, and 6 months and every
year thereafter. Restenosis60% or carotid occlusion were
considered adverse events. The adverse event rate was
determined per year in each group of patients (DS versus
BPPA). Subsequently, the event-free cumulative probabil-
ities in each time interval and their respective standard
Table II. Operative procedures in 517 CEAs (194 DS and 323 BPPA; 376 in male patients and 141 in female patients)
Operative procedures DS BPPA P value (2 test)
Male 178 (47.3%) 198 (52.7%) .001
Female 16 (11.3%) 125 (88.7%) .001
Shunt 42 (21.5%) 94 (21.1%) .06
Immediate surgical revision 3 (1.5%) 1 (0.3%) .12
Intimal tacking suture 27 (14.0%) 30 (9.3%) .10
Mean carotid occlusion time (minutes) 30  12.5 47  15.1
Table III. Postoperative complications within 30 days






Death 1* (0.5%) 3* (0.9%) .517
Stroke 8 (4.1%) 5 (1.5%) .066
TIA 7 (3.6%) 15 (4.6%) .57
*Four deaths for stroke.
TIA, Transient ischemic attack.
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errors were obtained. The values were plotted with a Kaplan-
Meier method curve with standard error bars (Fig 1).
A t test was used to compare the groups for each time
interval. The incidence rate of restenosis or occlusion was
lower in the BPPA group, and the difference between the
two groups was statistically significant at 6 months (P 
.017) and 1 year (P .009), but not after the second year.
None of the patients with carotid restenosis were symp-
tomatic. Fourteen cases (2.7%) had restenosis 80%, and
all underwent reoperation; in particular, 10 of the redo
operations were carried out on patients with DS at the time
of the first operation and four on patients with primary
BPPA. Four of the 14 redo operations were completed with
a primary closure, six with a new bovine pericardium patch
closure, and four with carotid stenting. The biologic inte-
gration of the patch was satisfactory in all cases. No deaths,
strokes, or transient ischemic attacks occurred after redo
operations (Table IV). One patient had severe restenosis 3
months after redo surgery; the patient is presently asymp-
tomatic and undergoing observation at 6 years from the
second operation.
DISCUSSION
The first reported clinical use of bovine pericardium
was in 1971 by Ionescu and coworkers,25 who developed a
prosthetic heart valve constructed from glutaraldhyde-pre-
served bovine pericardium. In time, the use of bovine
pericardium was extended to other surgical procedures in
different branches. Its importance has been emphasized
during cardiac surgery to repair a wide variety of congenital
cardiac defects,26 postinfarction septal rupture, left ventric-
ular aneurysmectomy, and mitral valve annuloplasty,27,28
during thoracic surgery to reduce postoperative air leaks,29
and during neurosurgical procedures with bovine pericar-
dium as a dural patch.19
We described our preliminary experience with bovine
pericardium in carotid patch angioplasty in 199622 and
more recently in 1999.30 In the peripheral vascular terri-
tory, the use of bovine pericardium has been reported for
reconstruction of the carotid, renal, iliac, femoral, and tibial
blood vessels and arteriovenous access. The material con-
sists of bovine pericardium, which has been cross linked
with glutaraldehyde to reduce antigenicity and to
strengthen and increase resistance to degradation. Patches
are available in a variety of sizes with thicknesses of approx-
imately 0.45 mm (Fig 2).
Fig 2. Picture shows rough (right) and smooth (left) sides of
pericardium patch.
Fig 1. Kaplan-Meier method curve: patients who were event free in two groups (at 9 years of follow-up study)
(Appendix, online only).
Table IV. Overall late restenosis rate in 9-year follow-up
study
Overall late restenosis rate DS BPPA
P value
(2 test)
Symptomatic restenosis 0 (0.0%) 0 (0.0%) –
Reoperations 10 (5.1%) 4 (1.2%) .008
Mortality after
reoperation
0 (0.0%) 0 (0.0%) –
Mean time of reoperation
(months)
31.3 59.5
Indication for reoperation: restenosis 80%.
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Bovine pericardia are procured from cattle of at least 1
year of age, with US Department of Agriculture guidelines
in the United States only. The raw pericardium is obtained
from intact pericardial sacs (Fig 3) and must meet strict
uniformity specifications. The pericardium then is sized and
treated with a glutaraldehyde solution to cross link the
tissue. This tissue is relatively acellular and made up of
primarily type I collagen; glutaraldehyde serves to bind
amine groups and to sterilize the product. Cross linking of
collagen molecules masks antigenic sites and sites that are
labile to protease cleavage, thereby retarding degrada-
tion.31 Further processing includes treatment with a solu-
tion of ethanol and propylene oxide, preserving sterility and
removing unincorporated glutaraldehyde. Residual glutar-
aldehyde at concentrations of 4 ppm in tissue culture media
has shown toxicity to fibroblasts.32 Residual testing on
bovine pericardium has shown less than 4 ppm glutaralde-
hyde, less than 100 ppm ethanol, and less than 13 ppm
propylene oxide after the recommended rinsing. In addi-
tion, ethanol pretreatment of glutaraldehyde-fixed xeno-
grafts has been shown to reduce calcification in applications
for bioprosthetic heart valves, possibly because of lipid
removal.33 Tissue products are stored in an aqueous solu-
tion of 1% propylene oxide.
The use of bovine pericardium has been extended to
peripheral vascular patching after primary cardiac applica-
tions. The typical mode of failure of the first bovine peri-
cardium implants used in the construction of heart valves
was mechanical failure as a result of calcium deposition.34
This may be activated by chemical mediators, such as the
phospholipid bilayer of cell membranes. Alternatively, the
mechanism for classification of cardiac valves fabricated
from glutaraldehyde cross-linked bovine pericardium has
been suggested to be associated with tissue stress fractures.
These fractures are the nucleation sites for calcium deposi-
tion.35 For peripheral vascular reconstruction, the patches
are not exposed to the same type of mechanical wear as in
the case of cardiac valves. The mechanical stress found in
peripheral applications are lower than those found in intra-
cardiac applications. Calcification reported for these types
of applications has been low.26,36,37
Another important issue in vascular patching is the
incidence of suture line bleeding. This phenomenon pro-
longs the time for hemostasis and may increase the inci-
dence of postoperative bleeding,27 which occurs when the
implant does not reapproximate around the suture after the
needle has penetrated, because cross-linked bovine pericar-
dium is relatively more compliant than currently available
synthetic materials and has the ability to comply with the
needle expansion and then return to its original dimen-
sions.38 Scanning electron micrographs show the ability of
bovine pericardium to reapproximate around a 6.0 prolene
suture (Fig 4). Minimal problems with suture line bleeding
with bovine pericardium have been reported,26,36,37,39 and
we had a similar experience in our more than 300 surgical
uses of bovine pericardium as carotid patch.
Aneurysm formation also is a concern in developing
biomaterials for vascular reconstruction in general. Aneu-
rysms can occur either at the anastomosis between the host
and the graft or within the body of the graft itself. The
occurrence of aneurysm at the host/graft interface has been
attributed in part to compliance mismatch between the two
materials.40 Comparative evaluations of graft material have
been performed and show that bovine heterografts can
have up to twice the compliance of either Dacron or
expanded polytetrafluoroethylene.38 In addition, the fi-
brous capsule that forms around a synthetic graft on im-
plantation does not have the mechanical integrity of either
the graft or the native artery.41
An aneurysmal dilatation of an arterial bovine hetero-
graft has been reported and has been attributed to graft
degeneration, partially as a result of graft antigenicity.42
Fig 3. Light micrograph shows cross section of Vascu-Guard at 200 magnification.
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Because pericardium is a relatively acellular tissue, the im-
munologic response is minimal. Although patch rupture
and aneurysm formation have been reported with the use of
saphenous vein and in synthetics, no reports of similar
phenomena with bovine pericardium have been found. The
adaptability of the pericardium patch to vascular suture and
its plasticity allow better configuration, especially at the
critical point of the distal arteriotomy on the internal ca-
rotid artery.
As described in detail in the introduction, our results
concerning infection, intraoperative blood loss, dilatation,
and recurrent stenosis compare favorably with the experi-
ences of other authors with different materials.12-19 The
cost of the bovine pericardium patch biologic material is
almost equivalent to the price of synthetic materials (Da-
cron: $120 to $210; bovine pericardium: $170 to $250;
polytetrafluoroethylene: $245 to $420).
CONCLUSION
The results we obtained during a 9-year period of CEA
procedures, with different surgical techniques, show that
BPPA is a suitable approach to carotid reconstruction and
compares favorably with other diffusely used patch materi-
als. Our experience is that the patch is easy to handle and
suture and is adaptable to the suture line. Data from the
literature suggest that bovine pericardium gives no signifi-
cant immunologic reaction, with good incorporation from
host tissue, nonthrombogenic inner surface, reduction of
adhesion formation, resisting suture line bleeding, and easy
handling like autogenous tissue, with no preclotting neces-
sitated. All these are valued characteristics that suggest the
elective use of a bovine pericardium patch. No rupture,
dilatation, or infection were observed. In our cases, the low
incidence rate of restenoses and the low short-term and
long-term morbidity rates that we have observed in our
9-year experience confirm the validity of this kind of patch
in the carotid bifurcation position and comply with the
guidelines set forth by the American Heart Association43
and the North American Symptomatic Carotid Endarter-
ectomy Trial.1 In conclusion, bovine pericardium patch is a
suitable material for CEA as an alternative to DS and other
biologic and synthetic patches.
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